SCHEMBL24649502

SCHEMBL24649502

COc1ccc(CN(Cc2ccc(OC)cc2)c2cc(C)c(Cl)c(Br)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.41
PIK3CD O00329 2/20 0.40
LMNA P02545 2/20 0.39
MAPT P10636 2/20 0.39
ALDH1A1 P00352 4/20 0.39
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
CHRM2 P08172 1/20 0.39
CYP3A4 P08684 1/20 0.39
HTR1A P08908 1/20 0.39
ADRA2A P08913 1/20 0.39
CYP2D6 P10635 1/20 0.39
TSHR P16473 1/20 0.39
DRD1 P21728 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
SLC6A4 P31645 1/20 0.39
CYP2C19 P33261 1/20 0.39
HRH1 P35367 1/20 0.39
OPRM1 P35372 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25982118 0.86 LMNA (0.41) PIK3CAPIK3CDLMNAMAPTALDH1A1
SCHEMBL30708392 0.84 LMNA (0.39) PIK3CAPIK3CDLMNAMAPTALDH1A1
SCHEMBL30708395 0.81 PIK3CD (0.43) PIK3CAPIK3CDLMNAMAPTALDH1A1
SCHEMBL21733449 0.81 LMNA (0.37) PIK3CAPIK3CDLMNAMAPTALDH1A1
SCHEMBL29384926 0.81 LMNA (0.37) PIK3CAPIK3CDLMNAMAPTALDH1A1
SCHEMBL30708390 0.81 LMNA (0.43) PIK3CALMNAMAPTALDH1A1MEN1
SCHEMBL31234710 0.81 PIK3CD (0.39) PIK3CAPIK3CDLMNAMAPTALDH1A1
SCHEMBL30708452 0.80 PDE2A (0.36) PIK3CAPIK3CDLMNAMAPTALDH1A1
SCHEMBL22029147 0.79 PIK3CD (0.42) PIK3CAPIK3CDLMNAMAPTALDH1A1
SCHEMBL23974786 0.79 PIK3CD (0.42) PIK3CAPIK3CDLMNAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250042919-A1 TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2025-02-06 US disclosed
EP-4291563-A1 TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF Genentech, Inc. (US) 2023-12-20 EP disclosed
CN-116867792-A Tetraepoxyazepine compound and use thereof 基因泰克公司 2023-10-10 CN disclosed
US-20220281893-A1 TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2022-09-08 US disclosed
WO-2022173678-A1 TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2022-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220281893-A1 TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF OXA1L, CACNA1I, GRIK5 PIK3CA 1315/4885PIK3CD 1545/4885LMNA 3975/4885
US-20250042919-A1 TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF OXA1L, CACNA1I, GRIK5 PIK3CA 1315/4885PIK3CD 1545/4885LMNA 3975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.